10 results about "Vesicular stomatitis virus VSV" patented technology

The application provides a virus envelope chimeric receptor and related biomaterials and applications thereof, and belongs to the technical field of molecular biology. Specifically disclosed is a virus envelope chimeric receptor, which comprises, in sequence, an antibody or antigen-binding fragment thereof, a hinge region, a transmembrane region and an intracellular region; the hinge region is selected from a hinge region composed of a hinge region of a CD8 molecule and a hinge region of a vesicular stomatitis virus envelope glycoprotein; the transmembrane region of the virus envelope chimeric receptor is selected from a transmembrane region of the vesicular stomatitis virus envelope glycoprotein; and the intracellular region of the virus envelope chimeric receptor is selected from an intracellular region of the vesicular stomatitis virus envelope glycoprotein. The virus envelope chimeric receptor is used for virus targeting, can improve the infection ability of viruses, reduces the infection rate of viruses on non-T cells to less than 5%, provides a safety guarantee for in-vivo CAR-T preparation, and can be used for industrial production.

The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV. Also provided is the use of a HEK293 cell line or a HEK293 cell line adapted to suspension growth for rescue of Vesicular Stomatitis Virus (VSV) or the use of a plasmid encoding SV40 Large T antigen for rescue of Vesicular Stomatitis Virus (VSV) in a HEK293 cell line or a HEK293 cell line adapted to suspension growth HEK293-F cells by means of transient transfection.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

This invention relates to the use of kaempferol and / or its metabolites in the preparation of antiviral drugs, wherein the viruses include any one or a combination of at least two of influenza A virus, vesicular stomatitis virus, severe fever with thrombocytopenia syndrome virus, or Crimean-Congo hemorrhagic fever virus. This invention demonstrates that kaempferol and its metabolites can enhance and prolong the type I IFN-activated JAK / STAT pathway, enhance innate immunity, and possess broad-spectrum antiviral activity.

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.

This application provides a recombinant oncolytic virus carrying a PD-1 / RGMb bispecific antibody, its preparation method, and its application. The preparation method includes the following steps: S1: preparing the plasmid pXN2-M51R-GFP; S2: obtaining the PD-1 / RGMb bispecific antibody sequence; S3: amplification of the Mouse PD-1 / RGMb bispecific antibody; S4: restriction enzyme digestion of the pXN2-M51R-GFP vector; S5: ligation of the target gene to the vector and transformation of the ligation system; S6: packaging of the recombinant vesicular stomatitis virus; S7: infection of Vero with the recombinant vesicular stomatitis virus; S8: resuspension and extraction of the target virus. In this application, the oncolytic virus is engineered using viral reverse genetics technology to design and construct a tandem PD-1 / RGMb bispecific antibody, which is then integrated into the vesicular stomatitis virus genome. This strategy aims to simultaneously block the PD-1 / PD-L1, PD-1 / PD-L2, and PD-L2 / RGMb signaling axes, thereby reshaping the immunosuppressive tumor microenvironment and synergistically enhancing the oncolytic virus-induced antitumor immune response.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

The application provides a recombinant oncolytic virus, a preparation method and a use thereof, wherein the recombinant oncolytic virus is rVSV M51R mIL27, in the application, by introducing IL-27 into the oncolytic vesicular stomatitis virus, on the one hand, the oncolytic vesicular stomatitis virus can be used as a delivery carrier to continuously express IL-27 in the tumor part, improve the effective concentration of IL-27 in the tumor microenvironment, and avoid systemic toxic side effects; on the other hand, IL-27 can synergize with the immune cell death induced by the oncolytic vesicular stomatitis virus to further enhance the antigen-specific T cell response and promote the transformation of tumor-infiltrating lymphocytes from an exhausted state to an effector state. Meanwhile, IL-27 helps to reshape the tumor immune microenvironment by inhibiting the immune suppressive cell population, thereby improving the overall immune response level. Therefore, the recombinant oncolytic virus provided in the application realizes multi-dimensional immune regulation of the tumor microenvironment through virus-mediated targeted delivery and continuous expression, thereby significantly improving the anti-tumor effect of the oncolytic virus therapy.

The application discloses a virus titer detection TCID 50 50 method, comprising the following steps: preparing a virus sample to be tested; diluting the virus to be tested with a culture medium; culturing cells; adding the diluted virus to be tested into the cells and continuing to culture the cells; observing the cell state every day; observing the cells under a microscope on the 6th-7th day; recording the number of cell wells with pathological changes; and calculating the TCID 50 50 value by using a formula, wherein the TCID 50 50 value is obtained; in the application, the wells added with the virus have pathological changes, the negative control group has no cell pathological changes, the application has specificity for specific viruses, linear regression analysis shows that the linear correlation is high, the application can be applied to virus titer detection of bovine viral diarrhea virus, vesicular stomatitis virus and bovine parainfluenza virus type 3, can promote in-depth development of virology research, accelerate the development process of vaccines, and more accurately carry out evaluation of antiviral drugs.